PDL Biopharma P/E Ratio

PDL Biopharma (PDLI) currently reports a P/E ratio of 0.0. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore PDL Biopharma's P/E ratio history and peer comparisons.

PDL Biopharma's P/E ratio of 0.0 is lower than the Healthcare sector average of 27.42. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates PDL Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At 0.0, PDLI can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 0.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for PDL Biopharma, and consider following PDLI for alerts when major investors trade the stock.

PDL Biopharma is classified in the Healthcare sector. On P/E ratio, it currently shows 0.0 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PDLI with unrelated industries.